Part of the
Stem Cell Revolution

Stem cells are expected to revolutionize the treatment of today's severe and incurable diseases. NextCell develops pioneering stem cell therapies for the treatment of autoimmune and inflammatory diseases as well as for use in organ transplants.

Technology

NextCell develops ProTrans™, a drug candidate consisting of stem cells for the treatment of autoimmune diseases, initially focusing on type- 1 diabetes. ProTrans is based on NextCell patent pending Selection Algorithm. Further, NextCell runs Cellaviva, Nordic's largest private stem cell bank, approved by IVO.
Read more

About NextCell

NextCell is a Swedish biopharmaceutical company running two business areas with the same core – stem cells from umbilical cord. NextCell is focusing on research and development of novel stem cell therapies and is also running a tissue establishment and primary biobank, classified as healthcare provider.
Read more

Investors

Like the IT-revolution has changed our way to handle data and communication, stem cells are expected to revolutionize almost any aspect of medicine including treatments for cancer, inflammatory and autoimmune disorders as well as regeneration of new tissues.
Read more
Read our latest report:
Q2 Report, 2019/2020
Download

News

2020-06-03

NextCell Pharma AB publishes prospectus relating to the rights issue and announces the intention of change of listing to Nasdaq First North in July

The Board of Directors of NextCell Pharma AB ("NextCell" or the “Company”) has prepared a prospectus (the “Prospectus”) relating to the new issue of shares with preferential rights for existing shareholders of approximately SEK 25.1 million (the Rights Issue”), which was resolved by the Board of ...
Read more
2020-05-28

Invited to panel discussion; Post-Covid-19 world

NextCell Pharma AB ("NextCell") has been invited to participate in the panel discussion entitled “The impact of corona virus on the global healthcare - new challenges and main problems”. Doctor Lindsay Davies, Chief Scientific Officer at NextCell and researcher at Karolinska Institutet will join ...
Read more
2020-05-15

The Board of Directors of NextCell Pharma AB resolves on a fully guaranteed SEK 25.1 million rights issue

NextCell Pharma AB ("NextCell" or the “Company”) announces that the Board of NextCell Pharma AB has resolved to conduct a fully guaranteed new issue of shares of approximately SEK 25.1 million with preferential rights for the Company's existing shareholders (the "Rights Issue"), subject to approv...
Read more
2020-04-29

NextCell Pharma AB publishes its interim report for September 2019 - February 2020

NextCell Pharma AB (publ) (NXTCL) today announces that its Interim report for the period September 1, 2019 - February 29, 2020 now is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-reports Second quarter (2019-12-01 until 2020-02-29) · Operating income...
Read more
All news